Cargando…

Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia

Bacterial infections of the respiratory tract constitute a major cause of death worldwide. Given the constant rise in bacterial resistance to antibiotics, treatment failure is increasingly frequent. In this context, innovative therapeutic strategies are urgently needed. Stimulation of innate immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Matarazzo, Laura, Casilag, Fiordiligie, Porte, Rémi, Wallet, Frederic, Cayet, Delphine, Faveeuw, Christelle, Carnoy, Christophe, Sirard, Jean-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465676/
https://www.ncbi.nlm.nih.gov/pubmed/31024555
http://dx.doi.org/10.3389/fimmu.2019.00723
_version_ 1783410977456259072
author Matarazzo, Laura
Casilag, Fiordiligie
Porte, Rémi
Wallet, Frederic
Cayet, Delphine
Faveeuw, Christelle
Carnoy, Christophe
Sirard, Jean-Claude
author_facet Matarazzo, Laura
Casilag, Fiordiligie
Porte, Rémi
Wallet, Frederic
Cayet, Delphine
Faveeuw, Christelle
Carnoy, Christophe
Sirard, Jean-Claude
author_sort Matarazzo, Laura
collection PubMed
description Bacterial infections of the respiratory tract constitute a major cause of death worldwide. Given the constant rise in bacterial resistance to antibiotics, treatment failure is increasingly frequent. In this context, innovative therapeutic strategies are urgently needed. Stimulation of innate immune cells in the respiratory tract [via activation of Toll-like receptors (TLRs)] is an attractive approach for rapidly activating the body's immune defenses against a broad spectrum of microorganisms. Previous studies of the TLR5 agonist flagellin in animal models showed that standalone TLR stimulation does not result in the effective treatment of pneumococcal respiratory infection but does significantly improve the therapeutic outcome of concomitant antibiotic treatment. Here, we investigated the antibacterial interaction between antibiotic and intranasal flagellin in a mouse model of pneumococcal respiratory infection. Using various doses of orally administered amoxicillin or systemically administered cotrimoxazole, we found that the intranasal instillation of flagellin (a dose that promotes maximal lung pro-inflammatory responses) induces synergistic rather than additive antibacterial effects against antibiotic–susceptible pneumococcus. We next set up a model of infection with pneumococcus that is resistant to multiple antibiotics in the context of influenza superinfection. Remarkably, the combination of amoxicillin and flagellin effectively treated superinfection with the amoxicillin-resistant pneumococcus since the bacterial clearance was increased by more than 100-fold compared to standalone treatments. Our results also showed that, in response to flagellin, the lung tissue generated an innate immune response even though it had been damaged by the influenza virus and pneumococcal infections. In conclusion, we demonstrated that the selective boosting of lung innate immunity is a conceptually advantageous approach for improving the effectiveness of antibiotic treatment and fighting antibiotic-resistant bacteria.
format Online
Article
Text
id pubmed-6465676
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64656762019-04-25 Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia Matarazzo, Laura Casilag, Fiordiligie Porte, Rémi Wallet, Frederic Cayet, Delphine Faveeuw, Christelle Carnoy, Christophe Sirard, Jean-Claude Front Immunol Immunology Bacterial infections of the respiratory tract constitute a major cause of death worldwide. Given the constant rise in bacterial resistance to antibiotics, treatment failure is increasingly frequent. In this context, innovative therapeutic strategies are urgently needed. Stimulation of innate immune cells in the respiratory tract [via activation of Toll-like receptors (TLRs)] is an attractive approach for rapidly activating the body's immune defenses against a broad spectrum of microorganisms. Previous studies of the TLR5 agonist flagellin in animal models showed that standalone TLR stimulation does not result in the effective treatment of pneumococcal respiratory infection but does significantly improve the therapeutic outcome of concomitant antibiotic treatment. Here, we investigated the antibacterial interaction between antibiotic and intranasal flagellin in a mouse model of pneumococcal respiratory infection. Using various doses of orally administered amoxicillin or systemically administered cotrimoxazole, we found that the intranasal instillation of flagellin (a dose that promotes maximal lung pro-inflammatory responses) induces synergistic rather than additive antibacterial effects against antibiotic–susceptible pneumococcus. We next set up a model of infection with pneumococcus that is resistant to multiple antibiotics in the context of influenza superinfection. Remarkably, the combination of amoxicillin and flagellin effectively treated superinfection with the amoxicillin-resistant pneumococcus since the bacterial clearance was increased by more than 100-fold compared to standalone treatments. Our results also showed that, in response to flagellin, the lung tissue generated an innate immune response even though it had been damaged by the influenza virus and pneumococcal infections. In conclusion, we demonstrated that the selective boosting of lung innate immunity is a conceptually advantageous approach for improving the effectiveness of antibiotic treatment and fighting antibiotic-resistant bacteria. Frontiers Media S.A. 2019-04-09 /pmc/articles/PMC6465676/ /pubmed/31024555 http://dx.doi.org/10.3389/fimmu.2019.00723 Text en Copyright © 2019 Matarazzo, Casilag, Porte, Wallet, Cayet, Faveeuw, Carnoy and Sirard. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Matarazzo, Laura
Casilag, Fiordiligie
Porte, Rémi
Wallet, Frederic
Cayet, Delphine
Faveeuw, Christelle
Carnoy, Christophe
Sirard, Jean-Claude
Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia
title Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia
title_full Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia
title_fullStr Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia
title_full_unstemmed Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia
title_short Therapeutic Synergy Between Antibiotics and Pulmonary Toll-Like Receptor 5 Stimulation in Antibiotic-Sensitive or -Resistant Pneumonia
title_sort therapeutic synergy between antibiotics and pulmonary toll-like receptor 5 stimulation in antibiotic-sensitive or -resistant pneumonia
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465676/
https://www.ncbi.nlm.nih.gov/pubmed/31024555
http://dx.doi.org/10.3389/fimmu.2019.00723
work_keys_str_mv AT matarazzolaura therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia
AT casilagfiordiligie therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia
AT porteremi therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia
AT walletfrederic therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia
AT cayetdelphine therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia
AT faveeuwchristelle therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia
AT carnoychristophe therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia
AT sirardjeanclaude therapeuticsynergybetweenantibioticsandpulmonarytolllikereceptor5stimulationinantibioticsensitiveorresistantpneumonia